Document Detail


Bendamustine compared to fludarabine as second-line treatment in chronic lymphocytic leukemia.
MedLine Citation:
PMID:  23340738     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Bendamustine demonstrated clinical activity in pre-treated hematological malignancies due to its unique mechanism of action distinct from standard alkylating agents. This study assessed its efficacy in patients with chronic lymphocytic leukemia pre-treated with an alkylator, in comparison to fludarabine. Patients with relapsed chronic lymphocytic leukemia requiring treatment after one previous systemic regimen (usually chlorambucil-based) were randomized to either receive bendamustine 100 mg/m(2) on days 1 and 2 of a 4-week cycle or standard fludarabine treatment consisting of 25 mg/m(2) on days 1 to 5 every 4 weeks. The primary objective was to achieve non-inferior progression-free survival (PFS) with bendamustine. Out of a total of 96 patients randomized, 92 were eligible, 49 allocated to bendamustine and 43 to fludarabine. About half of the patients received six or more cycles. Overall response rates were 76 % on bendamustine and 62 % on fludarabine, with clinical complete response rates of 27 and 9 %, respectively. Median PFS was 20.1 and 14.8 months (hazard ratio, 0.87; 90 % confidence interval, 0.60-1.27), median overall survival 43.8 and 41.0 months (hazard ratio, 0.82). Thrombocytopenia and gastrointestinal toxicities were marginally more frequent on bendamustine, albeit CTC grade 3/4 event incidence was similar. These data suggest at least comparable efficacy of bendamustine vs. fludarabine, pointing to an alternative treatment option in relapsing CLL patients after chlorambucil containing initial chemotherapy.
Authors:
Norbert Niederle; Dirk Megdenberg; Leopold Balleisen; Wolfgang Heit; Wolfgang Knauf; Johann Weiß; Werner Freier; Axel Hinke; Stefan Ibach; Hartmut Eimermacher
Related Documents :
17600868 - Merkel cell carcinoma: clinicopathological aspects of an unusual neoplasm.
24535158 - Nuclear-cytoplasmic parp-1 expression as an unfavorable prognostic marker in lymph node...
22941328 - Trends in patient characteristics, treatment and survival in breast cancer in a non-sel...
16200628 - Squamous cell carcinoma of the buccal mucosa: an aggressive cancer requiring multimodal...
3468888 - Acute tumor lysis syndrome in prolymphocytic leukemia.
9476688 - Cardiac angiosarcoma responding to multidisciplinary treatment.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-23
Journal Detail:
Title:  Annals of hematology     Volume:  -     ISSN:  1432-0584     ISO Abbreviation:  Ann. Hematol.     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-23     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9107334     Medline TA:  Ann Hematol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Medizinische Klinik III, Klinikum Leverkusen gGmbH, Am Gesundheitspark 11, D-51375, Leverkusen, Germany, niederle@klinikum-lev.de.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Probing the picosecond kinetics of the photosystem II core complex in vivo.
Next Document:  Auto-tandem catalysis: synthesis of 4H-pyrido[1,2-a]pyrimidin-4-ones via copper-catalyzed aza-Michae...